Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 6/20 | 0.47 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29864658 | 1.00 | MAPT (0.55) | MAPTSLC6A2SLC6A4SLC6A3KDM4E | |
| Hydrochloric Acid SCHEMBL10324019 | 0.97 | MAPT (0.53) | MAPTSLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL28799220 | 0.97 | MAPT (0.53) | MAPTSLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL10324020 | 0.91 | MAPT (0.49) | MAPTSLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL23610057 | 0.86 | SLC6A2 (0.63) | MAPTSLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL31143614 | 0.86 | SLC6A2 (0.63) | MAPTSLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL31143646 | 0.86 | SLC6A2 (0.63) | MAPTSLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL477369 | 0.86 | SLC6A2 (0.63) | MAPTSLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL9777431 | 0.84 | SLC6A2 (0.54) | MAPTSLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL4273441 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109046259-B | Modified mesoporous silica material, preparation method and application thereof | 上海海关工业品与原材料检测技术中心 | 2021-08-06 | — | — | CN | claimed |
| CN-102633821-B | copper complex built by pyrimidine carboxylic acid base ligand, preparation method and use of copper complex | UNIV NANJING INF SCI & TECH | 2014-08-06 | — | — | CN | claimed |
| CN-102633821-A | copper complex built by pyrimidine carboxylic acid base ligand, preparation method and use of copper complex | UNIV NANJING INF SCI & TECH | 2012-08-15 | — | — | CN | claimed |
| US-12116365-B2 | Heterocyclic compounds and uses thereof | Opna Bio SA (CH) | 2024-10-15 | — | — | US | disclosed |
| CN-114901646-B | Benzotriazine bisoxides and pharmaceutical compositions thereof | 浙江瑞臻医药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023019912-A9 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023019912-A9 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023019912-A1 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023019912-A1 | BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF | 杭州瑞臻医药有限公司 | 2023-02-23 | — | — | WO | disclosed |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Bio SA (CH) | 2022-11-10 | — | — | US | disclosed |
| EP-4071149-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Opna Immuno Oncology, SA (CH) | 2022-10-12 | — | — | EP | disclosed |
| US-6617299-B1 | Contacting the textile with a ligand which forms a complex with a transition metal, whereby the complex catalyses bleaching of the textile by atmospheric oxygen without use of aldehydes, wherein at | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2003-09-09 | — | — | US | disclosed |
| EP-1165738-A1 | COMPOSITION AND METHOD FOR BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000060044-A1 | COMPOSITION AND METHOD FOR BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2000-10-12 | — | — | WO | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0569598-A1 | BENZOXAZINONE DERIVATIVE | JAPAN TOBACCO INC. (JP) | 1993-11-18 | — | — | EP | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116365-B2 | Heterocyclic compounds and uses thereof | CYP11B2, CYP11B1, UGT2B7 | MAPT 2326/4885SLC6A2 2213/4885SLC6A4 3035/4885 |
| US-20220356183-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, CYP11B1, UGT2B7 | MAPT 2326/4885SLC6A2 2213/4885SLC6A4 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.